摘要
全球的肝硬化疾病负担很重,中国是全球肝硬化患者数量最多的国家。失代偿期肝硬化并发症如食管胃静脉曲张出血、自发性腹膜炎、肝性脑病及肝肾综合征等,常具备慢性多脏器功能不全的基础,这种慢加急性肝衰竭使患者生活质量差,危及生命。肝硬化门静脉高压既是肝硬化发展的后果,更是对肝硬化发展的二次打击甚至是叠加打击。有必要采用血管介入及研发新型药物早期降低肝内阻力,改善门静脉高压及患者预后。
Globally,the population living with liver cirrhosis is growing.There is the largest number of cirrhosis patients in China throughout the world.Acute-on-chronic liver failure(ACLF)is a clinical syndrome of sudden hepatic decompensations such as variceal bleeding,spontaneous bacterial peritonitis,hepatic encephalopathy and hepatorenal syndrome seen in patients with liver cirrhosis.ACLF leads to poor quality of life and high mortality.Portal hypertension is not only a consequence of the development of cirrhosis,but also a secondary or even superimposed attack to the development of cirrhosis.It is necessary to early reduce intrahepatic resistance by transjugular intrahepatic portosystemic shunt and drugs to improve the prognosis.
作者
唐承薇
TANG Chengwei(Department of Gastroenterology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2021年第12期2756-2759,共4页
Journal of Clinical Hepatology
关键词
高血压
门静脉
肝硬化
慢加急性肝功能衰竭
门体分流术
经颈静脉肝内
Hypertension,Portal
Liver Cirrhosis
Acute-On-Chronic Liver Failure
Portasystemic Shunt,Transjugular Intrahepatic